INDIANAPOLIS, May 15, 2024
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced
that Alonzo Weems, executive vice president of enterprise risk
management and chief ethics and compliance officer, and a member of
Lilly's Executive Committee, will retire after 27 years of service
with the company, effective Dec. 31, 2024. Weems will continue
to serve in his role while the company conducts an internal and
external search for a chief ethics and compliance officer.
"Throughout his distinguished career, Alonzo has been a
steadfast advocate for our company, providing strategic guidance to
our global product development teams and major geographies
worldwide," said David A. Ricks, Lilly's chair and CEO.
"His collaborative approach with leaders has helped us achieve
strong business performance while ensuring we uphold our values. As
our chief ethics and compliance officer, Alonzo has championed the
enhancement of our digital and data analytics capabilities and
fortified our ethics program. His commitment to winning with
integrity will leave a lasting legacy, and we thank him for his
many years of service."
Weems began his Lilly career in 1997 as an attorney in the
global medical and regulatory affairs legal group. Throughout his
career, he has held important leadership roles, including general
counsel for Lilly Canada, general
counsel for Lilly USA and the
Biomedicines and Diabetes business units, and vice president and
deputy general counsel for the corporate legal functions prior to
assuming his current role. Ethisphere recognized Lilly as one of
the World's Most Ethical Companies for the eighth year in a row in
2024, underscoring Weems' pivotal role in championing sustained
excellence in ethical practices across the organization.
About Lilly
Lilly is a medicine company turning
science into healing to make life better for people around the
world. We've been pioneering life-changing discoveries for nearly
150 years, and today our medicines help more than 51 million people
across the globe. Harnessing the power of biotechnology, chemistry
and genetic medicine, our scientists are urgently advancing new
discoveries to solve some of the world's most significant health
challenges: redefining diabetes care; treating obesity and
curtailing its most devastating long-term effects; advancing the
fight against Alzheimer's disease; providing solutions to some of
the most debilitating immune system disorders; and transforming the
most difficult-to-treat cancers into manageable diseases. With each
step toward a healthier world, we're motivated by one thing: making
life better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and
Lilly.com/news, or follow us
on Facebook, Instagram and
LinkedIn. C-LLY
Lilly Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements (as
that term is defined in the Private Securities Litigation Reform
Act of 1995), including those related to leadership changes and
Lilly's strategy, and reflects Lilly's current beliefs and
expectations. There can be no assurance that the leadership changes
will achieve Lilly's objectives or that Lilly will execute its
strategy as planned. For further discussion of risks and
uncertainties relevant to Lilly's business, please see Lilly's most
recent Forms 10-K and 10-Q filed with the U.S.
Securities and Exchange Commission. Lilly undertakes no duty to
update forward-looking statements.
Refer to:
|
Jordan Bishop;
jordan.bishop@lilly.com; 317-473-5712 (Media)
|
|
Joe
Fletcher; jfletcher@lilly.com; 317-296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alonzo-weems-to-retire-as-executive-vice-president-of-enterprise-risk-management-and-chief-ethics-and-compliance-officer-302145321.html
SOURCE Eli Lilly and Company